Cancer news

Latest news, press releases and blog posts from Cancer Research UK.

Brain Tumour Primary

Revamped drug may overcome resistance in brain tumours

Cancer Research UK scientists have taken steps to overcome drug resistance in glioblastoma, the most common type of brain tumour in adults.

Drug target discovered for aggressive childhood brain tumour

US scientists have successfully used an experimental drug to treat mice with an aggressive form of childhood brain cancer.

New computer method used to identify brain cancer gene

A new computer-based method of analysing biological data has been used to unearth the genetic roots of an aggressive form of brain cancer

Experimental brain tumour therapy considered for NHS fast track

A new brain cancer therapy has become the first in the UK to be deemed 'promising' as part of a scheme to speed up access to experimental treatments.

Brain tumour cells found circulating in blood

German scientists have discovered rogue brain tumour cells in patient blood samples.

Molecular imbalance linked to brain tumour seizures

Researchers in France may have discovered why some patients with a type of brain tumour have epileptic seizures.

Back in the news – mobile phones and cancer

Headlines yesterday suggesting heavy mobile phone use is ‘likely’ to cause cancer are misleading, and don’t reflect what the evidence really shows.

We’ve discussed...

Resurrecting stalled cancer drugs

Developing new drugs is tough. But as illustrated by the results of an early stage trial of a new vaccine for brain tumours, our Clinical Development Partnership (CDP)...

Our new strategy – “a big step towards putting us all out of jobs”

We asked our chief scientist, Professor Nic Jones, about why he’s so excited about our new research strategy, which we launched today.

Promising results in phase 1 trial lead immatics to continue work on vaccine (IMA950) for glioblastoma

A new cancer vaccine (IMA950) for glioblastoma has met the two primary endpoints of safety and immunogenicity in a Cancer Research UK trial.